View ValuationGuangdong Guanghua Sci-Tech 향후 성장Future 기준 점검 3/6Guangdong Guanghua Sci-Tech (는) 각각 연간 40.7% 및 12.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 41% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.6% 로 예상됩니다.핵심 정보40.7%이익 성장률41.00%EPS 성장률Chemicals 이익 성장29.3%매출 성장률12.5%향후 자기자본이익률14.57%애널리스트 커버리지Low마지막 업데이트15 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Yonghong Yan was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 31+ 1 more updateGuangdong Guanghua Sci-Tech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026공고 • Dec 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2025 Results on Oct 27, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025공고 • Sep 04Guangdong Guanghua Sci-Tech Co., Ltd. Approves Board ElectionsGuangdong Guanghua Sci-Tech Co., Ltd. its 1st Extraordinary General Meeting of 2025 on 02 September 2025 approved the election of Yan Yonghong, independent director and Xu Tao, independent director.공고 • Jul 02Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025공고 • Apr 24Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: 5F, No. 295, Daxue Road, Shantou, Guangdong China공고 • Mar 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025공고 • Dec 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025New Risk • Nov 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (0.8% operating cash flow to total debt). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).Board Change • Nov 12Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 31Third quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.27 loss in 3Q 2023)Third quarter 2024 results: CN¥0.01 loss per share (improved from CN¥0.27 loss in 3Q 2023). Revenue: CN¥663.0m (down 7.5% from 3Q 2023). Net loss: CN¥3.96m (loss narrowed 96% from 3Q 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024Reported Earnings • Aug 26Second quarter 2024 earnings released: EPS: CN¥0.017 (vs CN¥0.069 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.017 (up from CN¥0.069 loss in 2Q 2023). Revenue: CN¥658.5m (up 7.8% from 2Q 2023). Net income: CN¥6.94m (up CN¥34.5m from 2Q 2023). Profit margin: 1.1% (up from net loss in 2Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).공고 • Jun 29Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).공고 • Apr 29Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China공고 • Dec 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.062 profit in 3Q 2022)Third quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.062 profit in 3Q 2022). Revenue: CN¥733.1m (down 20% from 3Q 2022). Net loss: CN¥63.7m (down 361% from profit in 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2023 results on Oct 31, 2023Board Change • Sep 22Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.069 loss per share (vs CN¥0.12 profit in 2Q 2022)Second quarter 2023 results: CN¥0.069 loss per share (down from CN¥0.12 profit in 2Q 2022). Revenue: CN¥610.9m (down 39% from 2Q 2022). Net loss: CN¥27.6m (down 158% from profit in 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Reported Earnings • Mar 08Full year 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.16 in FY 2021)Full year 2022 results: EPS: CN¥0.30 (up from CN¥0.16 in FY 2021). Revenue: CN¥3.30b (up 28% from FY 2021). Net income: CN¥116.9m (up 88% from FY 2021). Profit margin: 3.5% (up from 2.4% in FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥0.062 (vs CN¥0.051 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.062 (up from CN¥0.051 in 3Q 2021). Revenue: CN¥914.5m (up 34% from 3Q 2021). Net income: CN¥24.4m (up 29% from 3Q 2021). Profit margin: 2.7% (down from 2.8% in 3Q 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Zhen Feng Liang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.049 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.049 in 2Q 2021). Revenue: CN¥1.01b (up 58% from 2Q 2021). Net income: CN¥47.2m (up 142% from 2Q 2021). Profit margin: 4.7% (up from 3.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Yuping Wu was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 01Second quarter 2021 earnings released: EPS CN¥0.049 (vs CN¥0.064 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥635.8m (up 3.9% from 2Q 2020). Net income: CN¥19.5m (down 20% from 2Q 2020). Profit margin: 3.1% (down from 4.0% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 17Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.04 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.01b (up 18% from FY 2019). Net income: CN¥36.6m (up 171% from FY 2019). Profit margin: 1.8% (up from 0.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Feb 27New 90-day high: CN¥13.98The company is up 6.0% from its price of CN¥13.19 on 27 November 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: CN¥12.32The company is down 17% from its price of CN¥14.81 on 18 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 27New 90-day low: CN¥12.97The company is down 6.0% from its price of CN¥13.75 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: CN¥13.21The company is down 3.0% from its price of CN¥13.55 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥706.8k, down 98% from the prior year. Total revenue was CN¥1.87b over the last 12 months, up 19% from the prior year.Is New 90 Day High Low • Oct 12New 90-day high: CN¥15.26The company is up 17% from its price of CN¥13.04 on 14 July 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period.이익 및 매출 성장 예측XSEC:002741 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,582463N/A341112/31/20273,982353N/A203112/31/20263,347253N/A-19013/31/20263,346120-219-137N/A12/31/20252,964104-7319N/A9/30/20252,800-121-2331N/A6/30/20252,701-159-1051N/A3/31/20252,665-184-2329N/A12/31/20242,589-205-85-31N/A9/30/20242,534-144-597N/A6/30/20242,605-204-124-44N/A3/31/20242,557-23871167N/A12/31/20232,699-43122127N/A9/30/20232,621-27015127N/A6/30/20232,802-18219171N/A3/31/20233,197-107-215-46N/A1/1/20233,302117-1818N/A9/30/20223,415120-14633N/A6/30/20223,184115-11119N/A3/31/20222,81587-2685N/A1/1/20222,58062-4744N/A9/30/20212,45164-1577N/A6/30/20212,27155-95-8N/A3/31/20212,24760-7615N/A12/31/20202,0143642125N/A9/30/20201,871124119N/A6/30/20201,829580183N/A3/31/20201,616-14-3669N/A12/31/20191,71414N/A58N/A9/30/20191,57638N/A19N/A6/30/20191,53166N/A16N/A3/31/20191,554122N/A51N/A12/31/20181,520135N/A-50N/A9/30/20181,578152N/A-28N/A6/30/20181,514134N/A-40N/A3/31/20181,397111N/A-32N/A12/31/20171,29993N/A71N/A9/30/20171,20886N/A4N/A6/30/20171,12678N/A32N/A3/31/20171,05266N/A41N/A12/31/201699263N/A43N/A9/30/201694663N/A125N/A6/30/201689859N/A28N/A3/31/201689159N/A-15N/A12/31/201586358N/A-68N/A9/30/201583064N/A-80N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 002741 의 연간 예상 수익 증가율(40.7%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 002741 의 연간 수익(40.7%)이 CN 시장(27.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 002741 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 002741 의 수익(연간 12.5%)이 CN 시장(연간 16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 002741 의 수익(연간 12.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 002741의 자본 수익률은 3년 후 14.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/12 06:15종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Guangdong Guanghua Sci-Tech Co., Ltd.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Wang ZheCitic Securities Co., Ltd.Zhe WangCitic Securities Co., Ltd.Qi ZhouHaitong International Research Limited1명의 분석가 더 보기
공고 • Jun 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Yonghong Yan was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 31+ 1 more updateGuangdong Guanghua Sci-Tech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
공고 • Dec 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2025 Results on Oct 27, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025
공고 • Sep 04Guangdong Guanghua Sci-Tech Co., Ltd. Approves Board ElectionsGuangdong Guanghua Sci-Tech Co., Ltd. its 1st Extraordinary General Meeting of 2025 on 02 September 2025 approved the election of Yan Yonghong, independent director and Xu Tao, independent director.
공고 • Jul 02Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025
공고 • Apr 24Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: 5F, No. 295, Daxue Road, Shantou, Guangdong China
공고 • Mar 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025
공고 • Dec 31Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
New Risk • Nov 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (0.8% operating cash flow to total debt). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
Board Change • Nov 12Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 31Third quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.27 loss in 3Q 2023)Third quarter 2024 results: CN¥0.01 loss per share (improved from CN¥0.27 loss in 3Q 2023). Revenue: CN¥663.0m (down 7.5% from 3Q 2023). Net loss: CN¥3.96m (loss narrowed 96% from 3Q 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
Reported Earnings • Aug 26Second quarter 2024 earnings released: EPS: CN¥0.017 (vs CN¥0.069 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.017 (up from CN¥0.069 loss in 2Q 2023). Revenue: CN¥658.5m (up 7.8% from 2Q 2023). Net income: CN¥6.94m (up CN¥34.5m from 2Q 2023). Profit margin: 1.1% (up from net loss in 2Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
공고 • Jun 29Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
공고 • Apr 29Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China
공고 • Dec 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.062 profit in 3Q 2022)Third quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.062 profit in 3Q 2022). Revenue: CN¥733.1m (down 20% from 3Q 2022). Net loss: CN¥63.7m (down 361% from profit in 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
공고 • Sep 30Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2023 results on Oct 31, 2023
Board Change • Sep 22Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.069 loss per share (vs CN¥0.12 profit in 2Q 2022)Second quarter 2023 results: CN¥0.069 loss per share (down from CN¥0.12 profit in 2Q 2022). Revenue: CN¥610.9m (down 39% from 2Q 2022). Net loss: CN¥27.6m (down 158% from profit in 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 08Full year 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.16 in FY 2021)Full year 2022 results: EPS: CN¥0.30 (up from CN¥0.16 in FY 2021). Revenue: CN¥3.30b (up 28% from FY 2021). Net income: CN¥116.9m (up 88% from FY 2021). Profit margin: 3.5% (up from 2.4% in FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥0.062 (vs CN¥0.051 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.062 (up from CN¥0.051 in 3Q 2021). Revenue: CN¥914.5m (up 34% from 3Q 2021). Net income: CN¥24.4m (up 29% from 3Q 2021). Profit margin: 2.7% (down from 2.8% in 3Q 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Zhen Feng Liang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.049 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.049 in 2Q 2021). Revenue: CN¥1.01b (up 58% from 2Q 2021). Net income: CN¥47.2m (up 142% from 2Q 2021). Profit margin: 4.7% (up from 3.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Yuping Wu was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 01Second quarter 2021 earnings released: EPS CN¥0.049 (vs CN¥0.064 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥635.8m (up 3.9% from 2Q 2020). Net income: CN¥19.5m (down 20% from 2Q 2020). Profit margin: 3.1% (down from 4.0% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 17Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.04 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.01b (up 18% from FY 2019). Net income: CN¥36.6m (up 171% from FY 2019). Profit margin: 1.8% (up from 0.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Feb 27New 90-day high: CN¥13.98The company is up 6.0% from its price of CN¥13.19 on 27 November 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: CN¥12.32The company is down 17% from its price of CN¥14.81 on 18 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 27New 90-day low: CN¥12.97The company is down 6.0% from its price of CN¥13.75 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: CN¥13.21The company is down 3.0% from its price of CN¥13.55 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.
Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥706.8k, down 98% from the prior year. Total revenue was CN¥1.87b over the last 12 months, up 19% from the prior year.
Is New 90 Day High Low • Oct 12New 90-day high: CN¥15.26The company is up 17% from its price of CN¥13.04 on 14 July 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period.